[2-chloro-11(4'-methylpiperazino)-dibenzo-(b,f)(1,4)-oxazepine (Sum 3170), a new neuroleptic. Results of clinical testing].
D000328:Adult; D000740:Anemia / Q000139:chemically induced; D001835:Body Weight / Q000187:drug effects; D002986:Clinical Trials as Topic; D003248:Constipation / Q000139:chemically induced; D003864:Depression, Chemical; D003984:Dibenzazepines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D006973:Hypertension / Q000139:chemically induced; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007022:Hypotension / Q000139:chemically induced; D007046:Hysteria / Q000188:drug therapy; D008607:Intellectual Disability / Q000188:drug therapy; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011618:Psychotic Disorders / Q000188:drug therapy; D012472:Salivation / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D013268:Stimulation, Chemical; D013546:Sweating / Q000187:drug effects; D013997:Time Factors; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014202:Tremor / Q000139:chemically induced; D014555:Urination Disorders / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D003984:Dibenzazepines; D006993:Hypnotics and Sedatives; D014149:Tranquilizing Agents
2-Chlor-11(4'-methylpiperazino)-dibenzo-(b,f)(1,4)-oxazepin (Sum 3170), ein neues Neurolepticum. Ergebnisse einer interklinischen Prüfung.